This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Orforglipron, an oral non-peptide GLP-1 agonist, reduced HbA1c by up to 1.48 percentage points and body weight by up to 7.6% in early type 2 diabetes over 40 weeks in the ACHIEVE-1 phase 3 trial.
Why it matters
This is the first phase 3 trial confirming that a non-injectable, non-peptide GLP-1 drug can produce clinically meaningful blood sugar and weight improvements. It could dramatically expand access to GLP-1 therapy by eliminating the need for injections.
The numbers in context
559 participants, mean baseline HbA1c 8.0%. HbA1c change: -1.24% (3 mg), -1.47% (12 mg), -1.48% (36 mg) vs. -0.41% (placebo). All p < 0.001. Weight: -4.5% (3 mg), -5.8% (12 mg), -7.6% (36 mg) vs. -1.7% (placebo). Mean HbA1c at 40 weeks: 6.5-6.7%. Discontinuation 4.4-7.8% vs 1.4% placebo.
How the study worked
Phase 3, double-blind, placebo-controlled RCT (ACHIEVE-1, NCT05971940). 1:1:1:1 randomization to orforglipron 3, 12, or 36 mg or placebo daily for 40 weeks. Primary endpoint: HbA1c change.
Who was studied
Adults with early type 2 diabetes treated with diet and exercise only (HbA1c 7.0-9.5%, BMI 23+)
What this study cannot tell us
No active comparator (injectable GLP-1 RA or oral semaglutide). 40-week duration. Patients with early T2D on diet/exercise only; may not represent broader population. GI adverse events higher with orforglipron.
Read the original research
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
The New England journal of medicine, 393(11), 1065-1076
Citation
Rosenstock, Julio; Hsia, Stanley; Nevarez Ruiz, Luis; Eyde, Sarah; Cox, David; Wu, Wen-Shuo; Liu, Rong; Li, Jianghao; Fernández Landó, Laura; Denning, Max; Ludwig, Lisa; Chen, Yanyun. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.. The New England journal of medicine, 393(11), 1065-1076. https://doi.org/10.1056/NEJMoa2505669